Market revenue in 2023 | USD 42.1 million |
Market revenue in 2030 | USD 115.5 million |
Growth rate | 15.5% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Kits & Reagents, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 54.39% in 2023. Horizon Databook has segmented the China mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
The mycoplasma testing market in China is saturated, despite the low cost of production drives global investments in the country for manufacturing. For instance, in December 2021, Fujifilm announced building a new center for bioprocessing media in China. This center was aiming to provide media for biotherapeutics development, advanced therapies, & vaccines. In addition, in October 2023, Eminence Biotechnology started a GMP-grade manufacturing facility of cell culture media in Suzhou.
Furthermore, in July 2024, Merck initiated a GMP-grade cell culture media manufacturing facility in China. With an investment of over USD 6 million, the facility was expected to support local biopharma manufacturing. Moreover, China is a pioneer in stem cell research, which is projected to drive the demand for mycoplasma testing.
The presence of global players, such as Thermo Fisher Scientific, Inc. & Merck KGaA, and local suppliers aids in meeting the diverse needs of R&D in the biopharmaceutical industry in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the China mycoplasma testing market , including forecasts for subscribers. This country databook contains high-level insights into China mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account